Sinus bradycardia
Conditions
Interventions
LT4 treatment group:Thyroxine supplementation therapy was used as the intervention. Patients in the LT4 trial group took a low dose of levothyroxine sodium tablets (Euthyrox) after enrollment, startin
DTE treatment group:Patients in the DTE trial group took a low dose of thyroid tablets after enrollment, starting at 20 mg. The target TSH control level was the same as above. The intervention lasted
Sponsors
Aerospace Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: This study intends to include patients aged 18 to 75 with sinus bradycardia who visited the Aerospace Center Hospital (including the outpatient and inpatient departments) from May 1, 2025 to December 29, 2026, and whose thyroid hormones were within the normal range. Inclusion criteria: 1.Age: 18-75 years old; 2. Sinus bradycardia (average HR of 24-hour ambulatory electrocardiogram <50bpm or ECG<50bpm, with normal P waves and a P wave to QRS complex ratio of 1:1); 3. Normal thyroid function (FT4 and TSH within the normal range).
Exclusion criteria
Exclusion criteria: 1.Patients with a history of malignant arrhythmias (such as sick sinus node syndrome, ventricular tachycardia, ventricular fibrillation, polymorphic ventricular premature beats, etc.); 2. Patients taking drugs that affect heart rate (various antiarrhythmic drugs including ivabradine, parasympathetic drugs such as acetylcholine, sympathetic nerve depressants such as clonidine, opioids and sedatives, etc.); 3. Diseases or drug treatments that interfere with the thyroid axis, such as amiodarone, etc 4. Patients with obstructive sleep apnea; 5. Stroke patients; 6. Patients with thoracic and lumbar spine trauma affecting the desympathetic tension of the heart; 7. Thyroid diseases, benign thyroid tumors, Hashimoto's thyroiditis and other thyroid diseases; 8. Severe anemia; 9. Severe liver and kidney function disorders; 10. Patients with a history of cancer 11. Patients with acute cardiac insufficiency; 12. Patients with acute myocardial infarction and those diagnosed with coronary heart disease; 13. Patients in the acute infection stage; 14. Pregnant women; 15. Patients who refuse to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average HR(24h holter);SF-36;QTc;SDNN;FT3;FT4;Thyroid hormones and related indicators;Anthropometric data: height, weight, waist circumference, hip circumference;IPAQ;Blood lipids;Blood cell count and proportions, hemoglobin count; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement rate of symptom; | — |
Countries
China
Contacts
Public ContactChunhua Ding
Aerospace Center Hospital
Outcome results
None listed